1. Molecular Testing in Ovarian Cancer: Is the Time Now?

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Basic Concepts

4. Overview of BRCA1 and BRCA2

5. Homologous Recombination Repair

6. Germline vs Somatic Mutations

7. Single- vs Multigene (Panel) Testing

8. Genetic Testing: Timing Faculty Recommendations

9. Case Study: Carla

10. Factors to Consider for Genetic Testing

11. Importance of Genetic Counseling

12. Case Study: Carla (cont)

13. Approach Upon Recurrence Faculty Recommendations

14. Case Study: Carla (cont)

15. PARP Inhibitors Overview

16. Predictors of PARP Activity

17. Olaparib in BRCAmut Advanced OC

18. Maintenance Olaparib vs Placebo SOLO2/ENGOT-OV21

19. Rucaparib in BRCAmut High-Grade OC Study 10 and ARIEL2 Combination Analysis

20. Rucaparib in gBRCAmut and sBRCAmut ARIEL2, Phase 2

21. Niraparib in HRD+ Advanced OC After Response To Platinum-Based Chemotherapy

22. Key Takeaways

23. Abbreviations

24. Abbreviations (cont)

25. Abbreviations (cont)

26. Abbreviations (cont)